Found Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

Is Found a Legitimate Medical Platform?

Found operates as a licensed telehealth company that connects patients with state-licensed prescribers. That makes it legally legitimate in the narrow regulatory sense. Whether it consistently meets clinical quality standards is a separate question, and one that public complaint records and regulatory context complicate.

How Found's Model Works

Found pairs an asynchronous or synchronous clinical consultation with a prescription for FDA-approved weight-loss agents, primarily GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound), alongside older oral options like naltrexone-bupropion (Contrave) and metformin. Patients complete an intake questionnaire, receive a prescriber review, and are matched to a medication and a coaching plan.

The FDA has approved semaglutide 2.4 mg (Wegovy) specifically for chronic weight management in adults with a BMI of 30 or higher, or BMI <30 with at least one weight-related comorbidity [1]. Any prescriber on Found's platform operating outside those labeled indications takes on off-label clinical risk that should be disclosed to the patient.

Regulatory and Licensing Framework

Telehealth prescribers must hold active licenses in the patient's state. The Ryan Haight Online Pharmacy Consumer Protection Act and subsequent DEA telehealth rules govern controlled-substance prescribing over video or asynchronous channels [2]. Found's prescribers are subject to those rules. State medical boards retain authority to discipline any physician or nurse practitioner who prescribes without adequate evaluation, regardless of platform.

LegitScript, the pharmacy and telehealth compliance certification body, offers a certification program for telehealth operators. Platforms that carry LegitScript certification have submitted to ongoing monitoring. Patients checking Found's current LegitScript status can verify it directly at legitscript.com, as certification status changes over time.

What GLP-1 Prescribing Data Actually Shows Across Platforms

No peer-reviewed study has published Found-specific prescribing outcomes. That absence is itself a data point. The clinical benchmarks come from the manufacturer-sponsored registration trials and independent analyses.

STEP Trial Benchmarks

The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001) [3]. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced a mean weight loss of 20.9% at 72 weeks versus 3.1% placebo (P<0.001) [4]. These are controlled-trial numbers under weekly titration protocols with trained clinical support.

Real-world telehealth outcomes tend to fall below trial benchmarks. A 2023 analysis published in JAMA Network Open examining real-world GLP-1 adherence found that 12-month persistence on injectable GLP-1 agents was approximately 40-50% across commercial insurance populations [5]. Discontinuation driven by cost, side effects, or prescription lapses directly erodes the weight loss possible from these agents.

Compounded Semaglutide: The Compliance Fracture Line

During the 2022-2024 FDA shortage period, many telehealth platforms, including some that partner with 503A and 503B compounding pharmacies, dispensed compounded semaglutide. The FDA's shortage list removal in early 2025 effectively ended the legal basis for most compounded semaglutide production [6]. The FDA stated clearly that compounded semaglutide "is not FDA-approved and has not been shown to be safe and effective" [6].

Any telehealth platform still routing patients to compounded semaglutide after the shortage designation ended may be operating outside FDA guidance. Patients who received compounded product from Found or any other platform during this window should confirm with their prescriber whether their current supply is FDA-approved.

Found Complaints: What Consumer Records Show

The BBB profile for Found Health, Inc. Reflects a recurring pattern of complaints. The three dominant complaint categories are billing disputes, cancellation difficulties, and prescription or medication delays.

Billing and Cancellation Patterns

Consumer complaint threads on the BBB and Trustpilot consistently describe difficulty canceling subscriptions after deciding to stop treatment. Some users report being charged for consultation fees or membership fees after submitting cancellation requests. These patterns are not unique to Found. Telehealth subscription models across the industry generate similar complaints, but the volume relative to the company's stated membership size matters when evaluating systemic risk.

The FTC's "click-to-cancel" rule, finalized in October 2024, requires that subscription cancellation be as easy as enrollment [7]. Telehealth platforms that make cancellation difficult are now explicitly subject to FTC enforcement action under that rule.

Prescription Delay Complaints

A second cluster of complaints involves patients who paid for a consultation and medication plan but experienced significant delays in receiving their prescription or medication. In a weight-management context, prescription gaps can trigger weight regain. The STEP-4 trial withdrawal data showed that patients who discontinued semaglutide 2.4 mg regained approximately two-thirds of their lost weight within 52 weeks of stopping [8]. That number illustrates why prescription continuity is a direct clinical issue, not merely a convenience one.

What Found Has Said Publicly

Found has cited BCBS insurance partnerships as evidence of clinical credibility, and insurance contracting does require some degree of clinical quality review. Blue Cross Blue Shield plans generally require telehealth vendors to meet network credentialing standards. That does not guarantee individual prescribing quality, but it does mean Found has cleared at least basic insurer vetting processes.

Clinical Quality Signals Worth Examining

Evaluating any telehealth weight-loss platform requires looking beyond marketing claims. The following framework applies equally to Found and its competitors.

Prescriber Credentials and Supervision Ratio

Board-certified obesity medicine specialists (ABOM diplomates) or endocrinologists bring deeper training to GLP-1 management than general practitioners doing asynchronous reviews. The American Board of Obesity Medicine has noted that adequate obesity pharmacotherapy management requires ongoing titration monitoring, side-effect counseling, and metabolic reassessment [9]. Platforms relying heavily on asynchronous questionnaire-based prescribing may not meet that standard.

The Obesity Medicine Association's clinical practice guidelines recommend individualizing GLP-1 dose titration based on tolerability, with standard semaglutide titration running 4-week intervals from 0.25 mg up to the 2.4 mg maintenance dose [10]. Patients should ask whether their assigned prescriber is reviewing titration data or whether the platform uses automated escalation.

Lab Work and Baseline Screening

FDA prescribing information for Wegovy recommends baseline assessment of thyroid history (given the rodent MTC signal), gallbladder disease history, pancreatitis history, and heart rate monitoring [1]. Platforms that skip baseline labs or medical history review to accelerate prescription turnaround may be cutting corners that create patient safety risk.

The Endocrine Society's 2023 obesity pharmacotherapy guidelines state that "clinicians should assess cardiovascular risk, renal function, and hepatic status before initiating GLP-1 receptor agonist therapy in patients with obesity" [11]. Found's intake process should, at minimum, capture these data points. Whether it does so consistently is not publicly verifiable from complaint data alone.

Behavioral Support Component

GLP-1 agents produce better long-term outcomes when combined with behavioral support. The STEP-5 trial (N=304, 104 weeks) demonstrated that semaglutide 2.4 mg combined with lifestyle intervention produced sustained 15.2% mean weight loss [12]. Found markets coaching as part of its offering. The clinical value of that coaching depends entirely on delivery quality, coach credentials, and session frequency, none of which are independently audited.

How Found Compares to FDA-Approved Weight-Loss Pharmacotherapy Standards

The FDA has approved five agents for long-term weight management in adults: orlistat, phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), liraglutide 3 mg (Saxenda), and semaglutide 2.4 mg (Wegovy), with tirzepatide 2.5-15 mg (Zepbound) added in 2023 [13]. Found's formulary reportedly includes several of these, alongside off-label options.

Matching Drug to Patient Profile

The 2023 American Gastroenterological Association (AGA) Clinical Practice Update on obesity pharmacotherapy recommends GLP-1 receptor agonists as first-line agents for patients with BMI >30 or BMI >27 with comorbidities, prioritizing agents with cardiovascular outcome trial data [14]. The SELECT trial (N=17,604) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in non-diabetic patients with obesity and established cardiovascular disease (HR 0.80, 95% CI 0.72-0.90, P<0.001) [15]. That kind of outcome data should factor into drug selection for appropriate patients.

Platforms that prescribe based solely on BMI without considering cardiovascular history, diabetes status, or prior medication response miss an opportunity to optimize treatment. Patients with type 2 diabetes, for example, may benefit more from tirzepatide's dual GIP/GLP-1 mechanism, as SURMOUNT-2 (N=938) showed 15.7% mean weight loss with tirzepatide 15 mg in that population [16].

Monitoring During Treatment

Once a GLP-1 agent is started, clinical monitoring should include weight checks every 4-12 weeks, assessment for GI side effects, blood pressure review, and heart rate tracking (semaglutide raises resting heart rate by a mean of 1-4 beats per minute in trials) [1]. Asynchronous telehealth platforms that do not schedule follow-up visits may not capture adverse signals early enough.

What BCBS Partnerships Mean for Patients

Found has publicly noted partnerships with Blue Cross Blue Shield plans in select markets. Insurance coverage changes the cost equation significantly. Without coverage, branded semaglutide 2.4 mg (Wegovy) costs approximately $1,350/month at retail. With commercial insurance coverage, patient out-of-pocket costs may drop to $25-$100/month using manufacturer savings programs, depending on plan design.

The American Heart Association's 2023 scientific statement on obesity and cardiovascular disease recommended that payers cover anti-obesity medications given the cardiovascular outcome evidence [17]. BCBS coverage expansion signals alignment with that recommendation. Patients should verify their specific plan's formulary before assuming coverage applies to their policy.

Red Flags and Green Flags for Any GLP-1 Telehealth Platform

Not every complaint is a red flag, and not every marketing claim is a green flag. Here is a clinically grounded way to evaluate Found or any competitor.

Green flags:

• Prescribers hold state licenses and ABOM certification or equivalent specialty training
• Intake process captures thyroid, pancreatitis, gallbladder, and cardiovascular history
• Titration follows FDA-labeled schedule with prescriber review at each step
• Cancellation policy is straightforward and in writing before payment
• Only FDA-approved drug products are dispensed (no compounded semaglutide post-shortage)

Red flags:

• No lab work or baseline screening required before prescription
• Automated prescription escalation without clinical review
• Compounded semaglutide offered after February 2025 without documented clinical justification
• Complaint volume on BBB skewed toward billing disputes rather than clinical concerns
• No follow-up appointments built into the program structure

The Regulatory Horizon for Telehealth GLP-1 Prescribing

The DEA's proposed telehealth prescribing rules, still being finalized as of early 2025, may require at least one in-person or synchronous video visit before certain prescriptions can be issued [2]. If those rules take effect, platforms relying heavily on asynchronous intake will need to restructure their clinical workflows. Patients enrolled in programs like Found's should monitor whether their platform adapts to these requirements or faces service disruptions.

The FTC's ongoing scrutiny of health subscription services adds another regulatory layer [7]. Platforms that have generated billing complaint patterns are more exposed to enforcement action under the revised unfair-or-deceptive-acts standards.